Stock Comparison

IFRX vs PFE

InflaRx NV vs Pfizer Inc

Who's the better investment? Let's break it down.

The Verdict

Dead heat.

Both stocks scored 4.0/10. You'll need to dig deeper into the qualitative factors to pick a winner here.

IFRX

InflaRx NV

4.0

out of 10

Proceed with Caution

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Want to compare any two stocks?

Valuation

IFRX

Metric

PFE

$81M

Market Cap

$146.4B

N/A

P/E Ratio

Lower may indicate better value

19.5

N/A

Forward P/E

8.1

1.4

Price/Book

1.5

N/A

EV/EBITDA

7.1

Profitability & Growth

IFRX

Metric

PFE

N/A

Profit Margin

11.8%

N/A

Gross Margin

74.8%

N/A

Operating Margin

15.4%

N/A

Return on Equity

8.4%

N/A

Return on Assets

3.6%

N/A

Revenue Growth

1.4%

N/A

EPS

$1.31

Financial Health

IFRX

Metric

PFE

N/A

Debt-to-Equity

Lower = less leverage

0.7

N/A

Current Ratio

Above 1.0 is healthy

1.2

N/A

Beta

Lower = less volatile

0.3

None

Dividend Yield

6.8%

Risk Comparison

IFRX

Overall

Aggressive

Financial

High

Market

Medium

Competitive

Medium

Execution

High

Regulatory

Low

PFE

Overall

Moderate

Financial

Low

Market

Low

Competitive

Medium

Execution

Low

Regulatory

Medium

What Could Go Wrong

The biggest risk for Pfizer is the ongoing and accelerated erosion of revenue from key patent expirations and declining COVID-related product sales (Paxlovid/Comirnaty). If the pipeline of new product...

Red Flags

🚩Adjusted EPS declined -18% YoY in Q1 2026 despite revenue beat, indicating continued margin pressure...
🚩High reliance on successful pipeline execution to offset significant revenue declines from mature pr...
🚩Market Cap ($146.42B) requires an unrealistic 10x growth to over $1.4 trillion in 3-5 years, a scale...

Competitive Moat

IFRX

Rating

🛡️ Narrow

Trend

➡️ Stable but vulnerable

Intangible Assets/IP (patent protection for vilobelimab, regulatory exclusivity from orphan drug designation)

PFE

Rating

🛡️ Wide

Trend

➡️ Stable

Intangible Assets/IP (Patents, regulatory approvals, proprietary compounds)Brand Power (Trust, reputation in healthcare)Cost Advantages (Scale in manufacturing and R&D)Switching Costs (Physician familiarity, established treatment protocols)

Investment Thesis

IFRX4.0/10

InflaRx represents an extremely high-risk, high-reward investment focused on the successful commercialization of its EU-approved orphan drug, Gohibic, for ANCA-associated vasculitis. Despite a clear market opportunity and unique drug profile, the company faces immediate existential financial challenges due to a critically short cash runway and slow sales uptake. A successful, non-dilutive financin...

Full IFRX Analysis

PFE4.0/10

If Pfizer's non-COVID product portfolio (e.g., Vyndaqel, Eliquis, newly launched oncology/rare disease drugs) continues to deliver mid-single-digit operational growth (above +5% YoY) and its late-stage pipeline yields 2-3 significant approvals (>$500M potential) over the next 18-24 months, then it could stabilize revenue around its $60B guidance range and see a modest re-rating to a 12-13x forward...

Full PFE Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

IFRX4.0/10

InflaRx (IFRX) remains a highly speculative, high-risk, high-reward biotech play with theoretical 10x potential if critical hurdles are overcome. The EU-approved orphan drug, Gohibic, for ANCA-associated vasculitis offers a strong market opportunity and a unique mechanism of action. However, the company's financial health is critically weak, with an estimated cash runway of 7-10 months remaining from March 2026. Commercialization of Gohibic continues to be slower than required to achieve self-su...

Full IFRX Analysis

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and Comirnaty contracts offer stability, but these are incremental gains for a company of Pfizer's scale....

Full PFE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.